bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
0 hedge funds and large institutions have $0 invested in bluebird bio in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $6.89K → $0 (-$6.89K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$6.89K |
| 2 |
Barclays
London,
United Kingdom
|
-$4 |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Russell Investments Group
London,
United Kingdom
| – | -$6.89K | -1,386 | Closed |
|
|
IA
2
IFP Advisors
Tampa,
Florida
| – | -$3 | -7 | Closed |
|
|
3
Barclays
London,
United Kingdom
| – | -$4 | -1 | Closed |
|
BLUE Hedge Fund Activity: Q3 2025 in Review
0 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2025, worth a combined $0 — down 100% from $6.89K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BLUE and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Russell Investments Group, exiting entirely with an estimated $6.89K sold.
- 0 institutional investors held bluebird bio (BLUE) as of Q3 2025, down from 3 in Q2 2025.
- Funds reported $0 of bluebird bio stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new bluebird bio positions in Q3 2025 and 3 closed out, a net change of -3 holders.
- The largest bluebird bio seller in Q3 2025 was Russell Investments Group, an estimated $6.89K sold.
Based on aggregated 13F filings for Q3 2025.